A5077665236- Renal Diseases and Glomerulopathies
- Autoimmune Bullous Skin Diseases
- Pregnancy and Medication Impact
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Pediatric Urology and Nephrology Studies
- Platelet Disorders and Treatments
- Chronic Kidney Disease and Diabetes
- Vasculitis and related conditions
- Systemic Lupus Erythematosus Research
- Urinary Bladder and Prostate Research
- Chronic Lymphocytic Leukemia Research
- Systemic Sclerosis and Related Diseases
- Renal Transplantation Outcomes and Treatments
- Immunodeficiency and Autoimmune Disorders
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Urinary Tract Infections Management
- Adolescent and Pediatric Healthcare
- Neonatal Health and Biochemistry
- Dialysis and Renal Disease Management
- Pelvic floor disorders treatments
- Electrolyte and hormonal disorders
- Urological Disorders and Treatments
- Celiac Disease Research and Management
- Birth, Development, and Health
- Biomedical Research and Pathophysiology
Saitama Children's Medical Center
2016-2025
National Center For Child Health and Development
2024
Yokohama City University Medical Center
2024
Yokohama City University
2024
Tokyo Metropolitan Children's Medical Center
2024
The Jikei University Hospital
2023
Juntendo University
2001-2023
Juntendo University Nerima Hospital
2005-2023
Juntendo University Urayasu Hospital
2023
Jikei University School of Medicine
2011-2015
Background X-linked Alport syndrome (XLAS) is a progressive hereditary nephropathy caused by mutations in the COL4A5 gene. Genotype-phenotype correlation male XLAS relatively well established; relative to truncating mutations, nontruncating exhibit milder phenotypes. However, transcript comparison between cases with splicing abnormalities that result premature stop codon and those has not been reported, mainly because analysis routinely conducted patients XLAS. Methods We examined expression...
<title>Abstract</title> <bold>Background</bold> Clinical practice guidelines for idiopathic nephrotic syndrome (NS) in children recommend twice-daily cyclosporine as a preferred steroid-sparing agent steroid-dependent (SDNS). Although single-daily (S-CS) may offer an effective therapeutic option with increased compliance and reduced nephrotoxicity, response predictors long-term outcomes following this regimen remain unclear cohort. <bold>Methods</bold> A retrospective study was conducted on...
Cyclosporine A (CsA) has been widely used in children with steroid dependent and resistant nephrotic syndrome (NS) because of its efficacy relieving these patients from systemic side effects steroids. However, long term use is controversial, since chronic CsA induced nephropathy (CsAN) may develop a considerable number patients.In order to clarify the risk factors for development CsAN, clinical characteristics or NS taking (target blood trough levels 50-150 ng/ml) more than six months,...
Rituximab (RTX) is regarded as a relatively safe and effective treatment for children with steroid-dependent nephrotic syndrome (SDNS). However, late-onset adverse events after RTX, including neutropenia, hypogammaglobulinemia, increased risk of infections, have been rarely reported in this cohort.This was single-center retrospective analysis during B-cell depletion periods single dose RTX (375 mg/m2) 60 patients complicated SDNS (total 126 doses). After maintenance therapy cyclosporine...
In view of the conflicting evidence helper T cell type 1 (Th1) or 2 (Th2) pattern cytokine synthesis in childhood idiopathic nephrotic syndrome (INS) this study examined balance Th1 and Th2 which are characterized by intracellular production interferon-gamma (IFNgamma) interleukin-4 (IL-4), respectively.Sixteen children with steroid-sensitive INS (mean age 9.0 years) were included study, together 15 healthy normal 7.9 for control group. Intracellular both IFNgamma IL-4 (CD4+ cell) was...